NLM Photonics adds Pangaea and Mitsubishi Chemical's Diamond Edge to seed backers
What's the deal? NLM PhotonicsDealroom has a profile for this one. Try Dealroom → has expanded its seed round with two new backers: Pangaea VenturesDealroom has a profile for this one. Try Dealroom → and Diamond Edge VenturesDealroom has a profile for this one. Try Dealroom →, the venture arm of Mitsubishi Chemical CorporationDealroom has a profile for this one. Try Dealroom →. The Seattle company develops organic electro-optic (OEO) technology based on its Selerion family of materials.
Who else is in? Existing investors Emerald Technology VenturesDealroom has a profile for this one. Try Dealroom →, Oregon Venture FundDealroom has a profile for this one. Try Dealroom →, IdemitsuDealroom has a profile for this one. Try Dealroom →, Tokyo Ohka Kogyo (TOK)Dealroom has a profile for this one. Try Dealroom →, and StoryHouse VenturesDealroom has a profile for this one. Try Dealroom → increased their stakes, alongside private investors and employees. David Weekes of Pangaea joins NLM's board.
What's the endgame? The capital will fund commercial-scale, multi-foundry production of organic hybrid photonic integrated circuits for high-speed optical transceivers, data center interconnects, and quantum computing. In 2025, NLM demonstrated the industry's first 1.6-terabit and 3.2-terabit multi-channel silicon-organic hybrid PICs.
Why now? The company frames its materials as a path to faster, more energy-efficient photonics, driven by surging AI workloads and demand for higher-bandwidth, lower-power optical interconnects.
Why it matters? NLM is the first company to secure investment from both Pangaea and Emerald, two established names across advanced materials and deep tech.
The signal: The mix of hard-tech investors and semiconductor-materials incumbents — TOK, IdemitsuDealroom has a profile for this one. Try Dealroom →, and Mitsubishi Chemical — points to a cap table built for both scientific innovation and volume manufacturing. "That combination of strong science and a credible path to scale is rare," Weekes said.
Read more: finanznachrichten.de
Image credit: Generated with Gemini
